MPL - Medicare private

 MPL - Medicare private

...............................

ASX:MPL (Medibank Private) has delivered resilient but maturing performance over the last 5 years, characterized by a steady share price, excellent capital management, and high profitability, despite short-term margin fluctuations. [1, 2, 3, 4, 5]

Profitability & Performance

• Profit: Medibank has remained a highly profitable, cash-generating business. In the last 12 months, it earned roughly $463.4 million in net income on $8.77 billion in revenue. While net margins swung from 6.27% (FY2021) down to 4.17% (FY2023) and back up during the period, underwriting profitability has generally remained resilient. [1, 2, 3]
• ROE: Return on Equity (ROE) has stayed exceptionally strong, generally hovering around the 20% to 26% mark, which sits favorably near its historical 10-year median. [1, 2]

Medibank (ASX:MPL) return on equity over the last 10 years

Approximate annual ROE based on reported fiscal-year results and market data sources.

For Medibank Private Limited, the key takeaway is not the exact year-to-year movement but the consistency:

• Average ROE over the decade: approximately 21%.
• Only one weak year: FY2023, when ROE fell to around 15% due to higher claims inflation and normalization after unusually favourable COVID-era conditions.
• Recovery was rapid: ROE returned above 21% in FY2024 and FY2025.
• Capital-light business model: Health insurance requires relatively little equity capital, allowing MPL to maintain ROEs well above the ASX average.
• Current ROE: around 20–22%, which places it among the stronger quality franchises on the ASX.

From a quality-investing perspective, MPL scores highly on:

• Sustained ROE above 20%.
• Very low financial leverage.
• Strong free cash generation.
• Consistent fully franked dividends.

The main risk to future ROE is health claims inflation outpacing premium increases approved by the government, which can compress margins for periods of time.

• Earnings.  Over the last 10 years, Medibank Private (ASX: MPL) earnings have seen consistent growth, though they fluctuated recently. The net profit after tax reached roughly $500.8 million in FY25, representing a 2% compound annual growth rate (CAGR) over the decade. Its adjusted earnings per share (EPS) sits around 18.2 cents. [1, 2, 3]
• 
  
  
  
  
• A detailed view of MPL’s financial performance over the past decade highlights this trend:
  Historical Earnings
  • FY25 Full-Year Results: Net profit after abnormals landed at $500.8 million. Health insurance operating profit continued to drive revenue, though cybercrime-related impacts remained a historical focus. [1, 2]
  • FY24 Full-Year Results: The company recorded a solid net profit after abnormals of $492.5 million, bouncing back robustly from the previous year. [1]
  • FY23 Full-Year Results: Net profit was heavily impacted by the late 2022 cyber incident, with statutory net profit dropping down to approximately $333 million. [1]
  • FY16–FY22 Period: MPL exhibited steady, reliable profit growth, with health insurance operating profits growing consistently, except for temporary disruptions during the peak COVID-19 pandemic years. [1]

• Stock Performance: Investors have enjoyed a solid long-term return, with the stock appreciating well over 100% over the last five years, currently trading around the $5.04 mark. [1, 2, 3]

Debt & Financial Health

• Low Debt: Medibank’s balance sheet is a major strength. The company operates with a very low Debt to Equity ratio of around 12%.
• Net Cash Position: Total cash holdings have consistently exceeded total debt over the last 5 years. This net-cash position provides strong financial stability and high liquidity. [1, 2]

Key Observations & Outlook (2026- forward)

• Maturing Market: The private health insurance sector in Australia is highly penetrated, limiting massive organic growth. To counter this, Medibank has been aggressively expanding into its 'Medibank Health' division (including the acquisitions of Myhealth and Better Medical) to secure new revenue streams. [1]
• Medibank Private (ASX: MPL) faces several material risks in the coming years, primarily driven by structural claims inflation, cost-of-living pressures, and ongoing regulatory constraints. These factors directly impact their margins and ability to grow policyholder bases. [1, 2]
  The primary challenges Medibank must navigate include:
  • Claims & Medical Inflation: Driven by an aging population, more frequent hospital treatments, and the adoption of expensive new medical technologies, healthcare costs are rising faster than general inflation. This places constant pressure on underwriting margins. [1]
  • Affordability & Cost-of-Living Pressures: As household budgets are stretched, policyholders may downgrade their level of coverage or drop private health insurance entirely to save money. The subsequent need to raise premiums to cover costs limits their ability to increase revenue without triggering mass customer attrition. [1, 2, 3]
  • Regulatory Intervention: The Federal Government strictly regulates and must approve all annual premium rate increases. During periods of high claims inflation, delayed or denied premium hikes restrict MPL’s pricing power. [1]
  • Intense Competition: The rise of third-party price aggregators and alternative mutual health funds makes it easier for customers to shop around for cheaper plans, leading to fierce member-retention challenges. [1, 2, 3]
  • Cybersecurity and Data Obligations: Following the highly publicized 2022 breach, MPL is carrying elevated technology and compliance costs. Lingering reputational impacts and ongoing class-action or regulatory lawsuits (such as proceedings with the OAIC) pose material tail risks to their bottom line. [1, 2]
  • Execution Risk in New Verticals: Medibank is expanding its footprint outside of traditional insurance into primary care and health services (e.g., the integration of the Better Medical clinic network). Operating these physical health hubs introduces new operational and capital management risks. [1, 2]

......................

The 10-year historical Price-to-Earnings (P/E) ratio for Medibank Private Limited (ASX: MPL) has fluctuated over a wide spectrum, ranging from a historical low of 14.38 to a peak of 43.0. Over the last decade, Medibank's historical trailing twelve months (TTM) median P/E ratio sits at 20.25. [1, 2]

As of July 2026, Medibank is trading at an elevated valuation with a current P/E ratio of approximately 29.7x to 30.0x, which is roughly 47% above its 10-year historical average. [1]

Annual Historical P/E Ratios (10-Year Trend)

The following table outlines the calendar year-end or fiscal-end P/E ratios for ASX: MPL tracking back over the past decade: [1, 2, 3]

Year	P/E Ratio (End of Year / Fiscal)	Valuation Context & Market Drivers
Current (July 2026)	29.7x – 30.1x	Premium valuation driven by elevated market caps and robust policyholder growth.
2025	43.0	Record high P/E ratio sparked by surging share price valuations vs compressed underlying margins.
2024	29.6	Valuation recovery post-cyberattack fallout as client numbers normalized.
2023	26.2	Under pressure due to the remediation costs and regulatory impacts of the late-2022 cyber breach.
2022	29.5	High-growth cycle pushed valuations higher as interest rate hikes boosted investment income portfolios.
2021	21.5	Normalized trading volume during late COVID-19 pandemic phases.
2020	19.8	Lower underwriting utilization during COVID lockdowns offset premium growth.
2019	21.2	Steady market performance aligned closely with its long-term average historical trend line.
2018	17.5	One of the lowest decade valuations, driven by regulatory uncertainty preceding federal elections.
2017	20.4	Moderate trading tracking the broader financial sector average indices.
2016	22.1	Steady multi-year baseline stabilization period following its 2014 initial public offering (IPO).

Key Valuation Statistics (Past 10 Years)

• 10-Year High: 43.0 (Recorded at the conclusion of 2025).
• 10-Year Median: 20.25.
• 10-Year Low: 14.38.
• Sector Peer Comparison: At ~30x earnings, Medibank trades at a significant premium compared to the broader Australian Insurance Industry average of 12.2x to 19.7x, though it sits below smaller peers like ClearView Wealth (~77x). [1, 2, 3, 4, 5]

Underlying Valuation Metrics

• Forward Outlook: Medibank's forward P/E ratio is projected to fall back to around 20.6x to 20.8x based on forecast consensus earnings growth of nearly 10%. [1, 2, 3]
• Dividend Yield Intersect: Medibank remains a favorite for income investors, paying a trailing yield of 3.3% to 4.2%. It has been increasing steadily since 2020 However, the current high payout ratio (around 99% to 110% of earnings) places intense pressure on earnings growth to sustain the premium valuation. [1, 2, 3]

..............................

-------------------